Alnylam Pharmaceuticals
ALNY
#728
Rank
NZ$60.52 B
Marketcap
NZ$452.31
Share price
2.55%
Change (1 day)
-41.91%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$6.60

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$6.70. In 2025 the company made an earnings per share (EPS) of NZ$3.18.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.60107.54%
2025NZ$3.18
2023NZ-$6.24-62%
2022NZ-$16.4229.03%
2021NZ-$12.72-3.36%
2020NZ-$13.16-8.48%
2019NZ-$14.387.67%
2018NZ-$13.3639.74%
2017NZ-$9.5612.94%
2016NZ-$8.4638.84%
2015NZ-$6.10-32.88%
2014NZ-$9.08259.44%
2013NZ-$2.53-31.25%
2012NZ-$3.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.41 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$4.52-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$75.15 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$1.01-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.29-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.48-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.42-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$1.43-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA